Seminar · Radiochemistry
Developing metal-based radiopharmaceuticals for imaging and therapy
Brett Paterson and Cormac Kelderman · Monash Biomedical Imaging
Thu, Jul 8, 2021 · 20:30 UTC
Personalised medicine will be greatly enhanced with the introduction of new radiopharmaceuticals for the diagnosis and treatment of various cancers, as well as cardiovascular disease and brain disorders. The unprecedented interest in developing theranostic radiopharmaceuticals is mainly due to the recent clinical successes of radiometal-based products including: • 177LuDOTA-TATE (trade name Lutathera, FDA approved in 2018), a peptide-based tracer that is used for treating metastatic neuroendocrine tumours • Ga 68 PSMA-11 (FDA approved in 2020), a positron emission tomography agent for imaging